2025
Short-term estradiol administration does not restore endothelin‐B receptor‐mediated vasodilation in postmenopausal women
Nuckols V, Shoemaker L, Kuczmarski A, Haigh K, McGinty S, Del Vecchio A, Schwab A, Edwards D, Taylor H, Wenner M. Short-term estradiol administration does not restore endothelin‐B receptor‐mediated vasodilation in postmenopausal women. AJP Heart And Circulatory Physiology 2025, 328: h327-h332. PMID: 39773019, PMCID: PMC12175985, DOI: 10.1152/ajpheart.00815.2024.Peer-Reviewed Original ResearchConceptsPostmenopausal womenExogenous estradiol administrationEndothelin B receptorEstradiol administrationPremenopausal womenLactated RingeHealthy postmenopausal womenYoung womenLaser Doppler flowmetryEndothelin-BVasodilatory responseTransdermal patchDoppler flowmetryCutaneous microcirculationVasodilationEstradiolAdministrationWomenReceptorsRingerBlockadeFlowmetry
2020
Lessons from KEEPS: the Kronos Early Estrogen Prevention Study
Miller VM, Taylor HS, Naftolin F, Manson JE, Gleason CE, Brinton EA, Kling JM, Cedars MI, Dowling NM, Kantarci K, Harman SM. Lessons from KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric 2020, 24: 139-145. PMID: 32880220, PMCID: PMC8108428, DOI: 10.1080/13697137.2020.1804545.Peer-Reviewed Original ResearchConceptsKronos Early Estrogen Prevention StudyCarotid intima-medial thicknessPrevention StudyCardiovascular diseaseOral conjugated equine estrogenClinical CVD eventsUse of MHTOvert cardiovascular diseasePlacebo-controlled trialConjugated equine estrogensCoronary artery calciumIntima-medial thicknessMode of deliveryUptake of estrogensMood/anxietyAge-related increaseGenetic variantsCVD eventsAgatston unitsArtery calciumSymptom reliefPlacebo pillsEquine estrogensMenopausal womenMenopausal symptomsHeart fat and carotid artery atherosclerosis progression in recently menopausal women: impact of menopausal hormone therapy: The KEEPS trial.
El Khoudary SR, Venugopal V, Manson JE, Brooks MM, Santoro N, Black DM, Harman M, Naftolin F, Hodis H, Brinton E, Miller V, Taylor H, Budoff M. Heart fat and carotid artery atherosclerosis progression in recently menopausal women: impact of menopausal hormone therapy: The KEEPS trial. Menopause The Journal Of The North American Menopause Society 2020, 27: 255-262. PMID: 32015261, PMCID: PMC7113029, DOI: 10.1097/gme.0000000000001472.Peer-Reviewed Original ResearchConceptsCarotid intima-media thicknessEpicardial adipose tissueProgression of atherosclerosisCIMT progressionHormone therapyAtherosclerosis progressionMenopausal womenOral conjugated equine estrogenParacardial adipose tissue volumeMenopausal hormone therapyPlacebo-controlled trialConjugated equine estrogensFat depositionIntima-media thicknessMcg/dAdipose tissue volumeRoute of administrationPAT changesCEE administrationPlacebo groupEquine estrogensT-E2Fat accumulationMonth progressionO-CEE
2019
Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback
Kling JM, Dowling NM, Bimonte-Nelson HA, Gleason CE, Kantarci K, Manson JE, Taylor HS, Brinton EA, Lobo RA, Cedars MI, Pal L, Neal-Perry G, Naftolin F, Harman SM, Miller VM. Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback. AJP Regulatory Integrative And Comparative Physiology 2019, 317: r912-r920. PMID: 31663769, PMCID: PMC6957372, DOI: 10.1152/ajpregu.00234.2019.Peer-Reviewed Original ResearchConceptsFollicle-stimulating hormoneKronos Early Estrogen Prevention StudyHormone levelsHormone therapyT-E2Menopausal womenTreatment groupsOral conjugated equine estrogenCommon hormone therapiesPituitary-ovarian hormonesPostmenopausal hormone therapyActive treatment groupConjugated equine estrogensMo of treatmentDouble-blinded treatmentPlacebo groupEquine estrogensMenopausal transitionPrevention StudyO-CEEHormonal modulationBaseline levelsCognitive declinePlaceboHormone formulations
2018
Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)
Cintron D, Lahr BD, Bailey KR, Santoro N, Lloyd R, Manson JE, Neal-Perry G, Pal L, Taylor HS, Wharton W, Naftolin F, Harman SM, Miller VM. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Menopause The Journal Of The North American Menopause Society 2018, 25: 145-153. PMID: 28832429, PMCID: PMC5771895, DOI: 10.1097/gme.0000000000000971.Peer-Reviewed Original ResearchConceptsKronos Early Estrogen Prevention StudyHormone therapyDomains of sleepSleep qualityDomain scoresMenopausal womenPrevention StudySleep domainsGlobal Pittsburgh Sleep Quality Index scoreOral conjugated equine estrogenPittsburgh Sleep Quality Index scorePittsburgh Sleep Quality IndexVasomotor symptom scoresConjugated equine estrogensSleep Quality IndexPoor sleep qualityGlobal sleep qualitySeverity of symptomsGlobal sleep scoreQuality Index scoresMenopausal hormonesVMS severityPostmenopausal womenVasomotor symptomsSpearman correlation coefficient
2017
Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS)
Taylor HS, Tal A, Pal L, Li F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Du W, Hodis HN, Lobo RA, Manson JE, Merriam GR, Miller VM, Naftolin F, Neal-Perry G, Santoro NF, Harman SM. Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA Internal Medicine 2017, 177: 1471-1479. PMID: 28846767, PMCID: PMC5710212, DOI: 10.1001/jamainternmed.2017.3877.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultDouble-Blind MethodEstradiolEstrogen Replacement TherapyEstrogensEstrogens, Conjugated (USP)FemaleFollow-Up StudiesGlucuronatesHumansMiddle AgedPostmenopauseProgesteroneProgestinsProspective StudiesPsychiatric Status Rating ScalesQuality of LifeRisk FactorsSexual Dysfunction, PhysiologicalTime FactorsWomen's HealthConceptsKronos Early Estrogen Prevention StudyLow sexual functionTransdermal estrogen therapySexual functionAncillary studiesEstrogen therapyPostmenopausal womenPrevention StudyT-E2Female Sexual Function InventoryOral conjugated equine estrogenOverall scoreLower FSFI scoresEarly postmenopausal womenMenopausal hormone therapyPlacebo-controlled trialOral micronized progesteroneConjugated equine estrogensSexual Function InventoryLast menstrual periodEffects of OralQuality of lifeProportion of womenSymptoms of distressMicronized progesteroneLongitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo
Santoro N, Allshouse A, Neal-Perry G, Pal L, Lobo RA, Naftolin F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Dowling NM, Dunn M, Gleason CE, Hodis HN, Isaac B, Magnani M, Manson JE, Miller VM, Taylor HS, Wharton W, Wolff E, Zepeda V, Harman SM. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo. Menopause The Journal Of The North American Menopause Society 2017, 24: 238-246. PMID: 27779568, PMCID: PMC5323337, DOI: 10.1097/gme.0000000000000756.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultAutonomic Nervous System DiseasesDrug Therapy, CombinationEstradiolEstrogen Replacement TherapyEstrogensEstrogens, Conjugated (USP)FemaleHot FlashesHumansIrritable MoodLongitudinal StudiesMiddle AgedPostmenopauseProgesteroneProgestinsSleep Initiation and Maintenance DisordersTreatment OutcomeVasomotor SystemConceptsOral conjugated estrogensActive treatment armsBody mass indexTreatment armsRace/ethnicityMonths postrandomizationNight sweatsPostmenopausal womenHot flashesMass indexMenopausal symptomsConjugated estrogensEarly postmenopausal womenMenopausal hormone therapyFinal menstrual periodProportion of womenHormone regimensTransdermal estradiolTransdermal estrogenHormone therapyVasomotor symptomsSymptom reliefTreat analysisActive treatmentConventional doses
2016
Effects of hormones on skin wrinkles and rigidity vary by race/ethnicity: four-year follow-up from the ancillary skin study of the Kronos Early Estrogen Prevention Study
Owen CM, Pal L, Mumford SL, Freeman R, Isaac B, McDonald L, Santoro N, Taylor HS, Wolff EF. Effects of hormones on skin wrinkles and rigidity vary by race/ethnicity: four-year follow-up from the ancillary skin study of the Kronos Early Estrogen Prevention Study. Fertility And Sterility 2016, 106: 1170-1175.e3. PMID: 27393520, DOI: 10.1016/j.fertnstert.2016.06.023.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultBlack or African AmericanDouble-Blind MethodDrug CombinationsElasticityEstradiolEstrogen Replacement TherapyEstrogens, Conjugated (USP)FemaleHumansMenopauseMiddle AgedProgesteroneSkinSkin AgingTime FactorsTransdermal PatchTreatment OutcomeUnited StatesWhite PeopleConceptsKronos Early Estrogen Prevention StudyConjugated equine estrogensHormone therapyRace/ethnicityRigidity scoresSkin wrinklesPrevention StudyOral conjugated equine estrogenWhite womenLowest wrinkle scoresPlacebo-controlled trialLast menstrual periodAcademic medical centerBlack womenWrinkle scoreEffects of hormonesEquine estrogensMenopausal womenMenstrual periodMedical CenterMAIN OUTCOMESkin rigidityWomenPlaceboScores
2014
Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial.
Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Cedars MI, Hopkins PN, Lobo RA, Manson JE, Merriam GR, Miller VM, Neal-Perry G, Santoro N, Taylor HS, Vittinghoff E, Yan M, Hodis HN. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Annals Of Internal Medicine 2014, 161: 249-60. PMID: 25069991, DOI: 10.7326/m14-0353.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultC-Reactive ProteinCarotid Intima-Media ThicknessCoronary Artery DiseaseDisease ProgressionDouble-Blind MethodEstradiolEstrogen Replacement TherapyEstrogensEstrogens, Conjugated (USP)FemaleHumansInsulin ResistanceLipidsMiddle AgedPostmenopauseProgesteroneRadiographyRisk FactorsSex Hormone-Binding GlobulinConceptsCarotid artery intima-media thicknessMenopausal hormone therapyCoronary artery calciumCVD riskMenopausal womenRisk factorsCardiovascular diseaseT-E2O-CEEHigh-density lipoprotein cholesterol levelsOral conjugated equine estrogenArtery intima-media thicknessEnd pointSex hormone-binding globulinCardiovascular risk factorsCVD risk factorsLipid-Lowering TherapyPrimary end pointSecondary end pointsSerious adverse eventsConjugated equine estrogensLipoprotein cholesterol levelsC-reactive proteinIntima-media thicknessHealthy menopausal womenThe KEEPS-Cognitive and Affective Study: Baseline Associations between Vascular Risk Factors and Cognition
Wharton W, Gleason CE, Dowling NM, Carlsson CM, Brinton EA, Santoro MN, Neal-Perry G, Taylor H, Naftolin F, Lobo RA, Merriam G, Manson JE, Cedars MI, Miller VM, Black DM, Budoff M, Hodis HN, Harman SM, Asthana S. The KEEPS-Cognitive and Affective Study: Baseline Associations between Vascular Risk Factors and Cognition. Journal Of Alzheimer’s Disease 2014, 40: 331-341. PMID: 24430001, PMCID: PMC4367860, DOI: 10.3233/jad-130245.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultAttentionBlood GlucoseBlood PressureCholesterol, HDLCholesterol, LDLCognition DisordersDouble-Blind MethodEstradiolEstrogensFemaleHormonesHumansLongitudinal StudiesMiddle AgedMood DisordersNeuropsychological TestsPsychiatric Status Rating ScalesRisk FactorsConceptsVascular risk factorsSystolic blood pressureBlood pressureRisk factorsAlzheimer's diseaseCognitive dysfunctionMidlife vascular risk factorsOral conjugated equine estrogenHigher systolic blood pressureConjugated equine estrogensLower blood pressureSerum estradiol levelsHigh blood pressurePostmenopausal womenVascular riskBP levelsEquine estrogensEstradiol levelsMenopausal womenParallel groupClinical trialsHormone levelsCognitive domainsBaseline associationsCognitive decline
2009
Using Basic Science to Design a Clinical Trial: Baseline Characteristics of Women Enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)
Miller VM, Black DM, Brinton EA, Budoff MJ, Cedars MI, Hodis HN, Lobo RA, Manson JE, Merriam GR, Naftolin F, Santoro N, Taylor HS, Harman SM. Using Basic Science to Design a Clinical Trial: Baseline Characteristics of Women Enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Journal Of Cardiovascular Translational Research 2009, 2: 228-239. PMID: 19668346, PMCID: PMC2721728, DOI: 10.1007/s12265-009-9104-y.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultCardiovascular DiseasesDouble-Blind MethodEstradiolEstrogen Replacement TherapyEstrogens, Conjugated (USP)FemaleHumansMiddle AgedProgesteroneProspective StudiesPulse Therapy, DrugResearch DesignRisk AssessmentRisk FactorsSex FactorsTime FactorsTranslational Research, BiomedicalTreatment OutcomeUnited StatesWomen's HealthConceptsKronos Early Estrogen Prevention StudyMenopausal hormone therapyClinical trialsEpidemiological studiesWomen's Health Initiative hormone trialsEstrogen Replacement StudyYears of menopauseCardiovascular disease riskProgression of atherosclerosisDemographics of womenBasic science studiesTiming of initiationMechanism of actionKEEP participantsMHT useBaseline characteristicsHormone therapyProspective trialPrevention StudyHormone trialsCardiovascular diseaseBasic science informationDisease riskParticipant demographicsAdverse effects
2007
Exogenous oestradiol and progesterone administration does not cause oedema in healthy young women
Stachenfeld NS, Taylor HS. Exogenous oestradiol and progesterone administration does not cause oedema in healthy young women. Clinical Endocrinology 2007, 66: 410-418. PMID: 17302877, DOI: 10.1111/j.1365-2265.2007.02748.x.Peer-Reviewed Original ResearchConceptsExtracellular fluid volumeTranscapillary albumin escape rateGonadotropin-releasing hormone antagonistPmol/Plasma renin activitySerum aldosterone concentrationHealthy young womenAlbumin escape rateRenin activityAldosterone concentrationGnRH antagonistHealthy womenProgesterone administrationExogenous oestradiolIntravascular volumeHormone antagonistProgesterone increaseDay 2Day 5Hormone treatmentOestradiolDay 13Extravascular componentOncotic pressureYoung women
2003
Oestrogen effects on urine concentrating response in young women
Stachenfeld NS, Taylor HS, Leone CA, Keefe DL. Oestrogen effects on urine concentrating response in young women. The Journal Of Physiology 2003, 552: 869-880. PMID: 12923212, PMCID: PMC2343447, DOI: 10.1113/jphysiol.2003.046920.Peer-Reviewed Original ResearchConceptsAVP infusionRenal sensitivityHormone treatmentDistal tubular sodium reabsorptionRenal free water clearanceRenal fluid retentionTubular sodium reabsorptionFree water clearancePlasma AVP concentrationArginine vasopressin releaseRate of clearancePhysiological rangeOE2 treatmentSodium excretionGnRHa administrationSodium reabsorptionEstrogen effectsEstrogen treatmentFluid retentionLeuprolide acetateWater clearanceRenal waterAVP concentrationVasopressin releaseUrine osmolality
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply